Compare ANY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANY | APVO |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.3M |
| IPO Year | 2020 | 2023 |
| Metric | ANY | APVO |
|---|---|---|
| Price | $1.36 | $4.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 629.9K | 34.8K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,608,000.00 | $3,114,000.00 |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.25 |
| 52 Week High | $1.94 | $13.11 |
| Indicator | ANY | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 33.95 |
| Support Level | $0.47 | $2.85 |
| Resistance Level | $1.92 | $7.65 |
| Average True Range (ATR) | 0.16 | 0.38 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 9.22 | 18.86 |
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.